Top

Neurological Sciences

Published in:

01-01-2020 | Parkinson's Disease | Original Article

Rasagiline combined with levodopa therapy versus levodopa monotherapy for patients with Parkinson’s disease: a systematic review

Authors: De-Qi Jiang, Hua-Kun Wang, Yan Wang, Ming-Xing Li, Li-Lin Jiang, Yong Wang

Published in: Neurological Sciences | Issue 1/2020

Abstract

Objective

The aim of this report was to systematically evaluate the efficacy and safety of rasagiline (R) plus levodopa (l) (R + l) for the treatment of Parkinson’s disease (PD) compared with that of l monotherapy, in order to provide a reference resource for rational drug use.

Methods

Randomized controlled trials (RCTs) of R + l for PD published up to September 2018 were searched. Sensitivity analyses were also performed.

Results

Fourteen RCTs with 2531 participants were included. Compared with l monotherapy, the pooled effects of R + l combination therapy on unified Parkinson’s disease rating scale (UPDRS) score were (SMD − 0.50, 95% CI − 0.70 to − 0.30, P < 0.00001) for UPDRS motor score, (SMD − 0.59, 95% CI − 0.79 to − 0.39, P < 0.00001) for UPDRS activities of daily living (ADL) score, (SMD − 0.65, 95% CI − 0.81 to − 0.49, P < 0.00001) for UPDRS total score. R + l combination therapy was better than l monotherapy in reducing daily off-time (SMD − 1.15, 95% CI − 2.13 to − 0.17, P = 0.02), but there was a statistically nonsignificant result in daily on-time increase (SMD 1.39, 95% CI − 0.69 to 3.48, P = 0.19). There were no statistical differences in number of adverse events (OR 1.33, 95% CI 0.97 to 1.82, P = 0.07) and number of dropout (OR 0.88, 95% CI 0.65 to 1.19, P = 0.39) between R + l combination therapy and l monotherapy.

Conclusions

R + l combination therapy was superior to l monotherapy for improvement of UPDRS scores and off-time in PD patients. Moreover, R + l combination therapy and l monotherapy were similar in terms of safety and tolerability.

Available only for authorised users

Venkateshappa C, Harish G, Mythri RB, Mahadevan A, Bharath MM, Shankar SK (2012) Increased oxidative damage and decreased antioxidant function in aging human substantia nigra compared to striatum: implications for Parkinson’s disease. Neurochem Res 37(2):358–369PubMedCrossRef

Ikeda K, Yoshikawa S, Kurokawa T, Yuzawa N, Nakao K, Mochizuki H (2009) TRK-820, a selective kappa opioid receptor agonist, could effectively ameliorate L-DOPA-induced dyskinesia symptoms in a rat model of Parkinson’s disease. Eur J Pharmacol 620(1–3):42–48PubMedCrossRef

Cheung C, Bhimani R, Wyman JF, Konczak J, Zhang L, Mishra U, Terluk M, Kartha RV, Tuite P (2018) Effects of yoga on oxidative stress, motor function, and non-motor symptoms in Parkinson’s disease: a pilot randomized controlled trial. Pilot Feasibility Stud 4:162PubMedPubMedCentralCrossRef

Nagatsua T, Sawadab M (2009) L-dopa therapy for Parkinson’s disease: past, present, and future. Parkinsonism Relat Disord 15(Suppl 1):S3–S8PubMedCrossRef

Marsili L, Marconi R, Colosimo C (2017) Treatment strategies in early Parkinson’s disease. Int Rev Neurobiol 132:345–360PubMedCrossRef

Bendi VS, Shou J, Joy S, Torres-Russotto D (2018) Motor fluctuations and levodopa-induced dyskinesias in dopa-responsive dystonia. Parkinsonism Relat Disord 50:126–127PubMedCrossRef

Szökő É, Tábi T, Riederer P, Vécsei L (2018) Pharmacological aspects of the neuroprotective effects of irreversible MAO-B inhibitors, selegiline and rasagiline, in Parkinson’s disease. J Neural Transm (Vienna) 125(11):1735–1749CrossRef

Robakis D, Fahn S (2015) Defining the role of the monoamine oxidase-B inhibitors for Parkinson’s disease. CNS Drugs 29(6):433–441PubMedCrossRef

Youdim MB, Gross A, Finberg JP (2001) Rasagiline [N-propargyl-1R(+)-aminoindan], a selective and potent inhibitor of mitochondrial monoamine oxidase B. Br J Pharmacol 132(2):500–506PubMedPubMedCentralCrossRef

10.

McCormack PL (2014) Rasagiline: a review of its use in the treatment of idiopathic Parkinson’s disease. CNS Drugs 28(11):1083–1097PubMedCrossRef

11.

Youdim MB, Bar Am O, Yogev-Falach M, Weinreb O, Maruyama W, Naoi M, Amit T (2005) Rasagiline: neurodegeneration, neuroprotection, and mitochondrial permeability transition. J Neurosci Res 79(1–2):172–179PubMedCrossRef

12.

Magyar K, Stocchi F, Fossati C, Torti M (2015) Rasagiline for the treatment of Parkinson’s disease: an update. Expert Opin Pharmacother 16(14):2231–2241CrossRef

13.

Pistacchi M, Martinello F, Gioulis M, Zambito Marsala S (2014) Rasagiline and rapid symptomatic motor effect in Parkinson’s disease: review of literature. Neurol Ther 3(1):41–66PubMedCrossRef

14.

Weinreb O, Amit T, Sagi Y, Drigues N, Youdim MB (2009) Genomic and proteomic study to survey the mechanism of action of the anti-Parkinson’s disease drug, rasagiline compared with selegiline, in the rat midbrain. J Neural Transm (Vienna) 116(11):1457–1472CrossRef

15.

Hattori N, Takeda A, Takeda S, Nishimura A, Kitagawa T, Mochizuki H, Nagai M, Takahashi R (2019) Rasagiline monotherapy in early Parkinson’s disease: a phase 3, randomized study in Japan. Parkinsonism Relat Disord 60:146–152PubMedCrossRef

16.

Barone P, Santangelo G, Morgante L, Onofrj M, Meco G, Abbruzzese G, Bonuccelli U, Cossu G, Pezzoli G, Stanzione P, Lopiano L, Antonini A, Tinazzi M (2015) A randomized clinical trial to evaluate the effects of rasagiline on depressive symptoms in non-demented Parkinson’s disease patients. Eur J Neurol 22(8):1184–1191PubMedPubMedCentralCrossRef

17.

Frakey LL, Friedman JH (2017) Cognitive effects of rasagiline in mild-to-moderate stage Parkinson’s disease without dementia. J Neuropsychiatry Clin Neurosci 29(1):22–25PubMedCrossRef

18.

Moher D, Liberati A, Tetzlaff J, Altman DG, The PRISMA Group (2009) Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med 6(7):e1000097PubMedPubMedCentralCrossRef

19.

Jadad AR, Moore RA, Carroll D, Jenkinson C, Reynolds DJ, Gavaghan DJ, McQuay HJ (1996) Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials 17(1):1–12PubMedCrossRef

20.

Moher D, Pham B, Jones A, Cook DJ, Jadad AR, Moher M, Tugwell P, Klassen TP (1998) Does quality of reports of randomised trials affect estimates of intervention efficacy reported in meta-analyses? Lancet 352(9128):609–613CrossRefPubMed

21.

Jiang DQ, Zhao SH, Li MX, Jiang LL, Wang Y, Wang Y (2018) Prostaglandin E1 plus methylcobalamin combination therapy versus prostaglandin E1 monotherapy for patients with diabetic peripheral neuropathy: a meta-analysis of randomized controlled trials. Medicine (Baltimore) 97(44):e13020CrossRef

22.

Higgins JP, Thompson SG (2002) Quantifying heterogeneity in a meta-analysis. Stat Med 21(11):1539–1558PubMedCrossRef

23.

Parkinson Study Group (2005) A randomized placebo-controlled trial of rasagiline in levodopa-treated patients with Parkinson disease and motor fluctuations: the PRESTO study. Arch Neurol 62(2):241–248CrossRef

24.

Han Z (2016) Evaluate efficacy and safety of rasagiline mesylate tablets in treatment of idiopathic Parkinson’s disease in the basis of treatment of levodopa. Dissertation, Shanxi Medical University

25.

Hanagasi HA, Gurvit H, Unsalan P, Horozoglu H, Tuncer N, Feyzioglu A, Gunal DI, Yener GG, Cakmur R, Sahin HA, Emre M (2011) The effects of rasagiline on cognitive deficits in Parkinson’s disease patients without dementia: a randomized, double-blind, placebo-controlled, multicenter study. Mov Disord 26(10):1851–1858PubMedCrossRef

26.

Hauser RA, Stocchi F, Rascol O, Huyck SB, Capece R, Ho TW, Sklar P, Lines C, Michelson D, Hewitt D (2015) Preladenant as an adjunctive therapy with levodopa in Parkinson disease: two randomized clinical trials and lessons learned. JAMA Neurol 72(12):1491–1500CrossRefPubMed

27.

Li F, Chen M, Ma XT, Li XG, Tan H, He XY, Yuan P (2014) Efficacy and safety of rasagiline mesylate in treatment of idiopathic Parkinson’s disease with motor fluctuations: a randomized, double-blind, parallel-controlled, single-center trial. J Third Mil Med Univ 36(7):696–699

28.

Liao PJ (2014) Clinical observation of efficacy of rasagiline mesylate combined with levodopa in the treatment of primary Parkinson’s disease with motor fluctuations. Prac J Card Cereb Pneumal Vasc Dis 22(9):78–79

29.

Lim TT, Kluger BM, Rodriguez RL, Malaty IA, Palacio R Jr, Ojo OO, Patel S, Gujrati Y, Nutter B, Swartz C, Hennessy C, Fernandez HH (2015) Rasagiline for the symptomatic treatment of fatigue in Parkinson’s disease. Mov Disord 30(13):1825–1830PubMedCrossRef

30.

Rabey JM, Sagi I, Huberman M, Melamed E, Korczyn A, Giladi N, Inzelberg R, Djaldetti R, Klein C, Berecz G (2000) Rasagiline mesylate, a new MAO-B inhibitor for the treatment of Parkinson’s disease: a double-blind study as adjunctive therapy to levodopa. Clin Neuropharmacol 23(6):324–330PubMedCrossRef

31.

Rascol O, Brooks DJ, Melamed E, Oertel W, Poewe W, Stocchi F, Tolosa E (2005) Rasagiline as an adjunct to levodopa in patients with Parkinson’s disease and motor fluctuations (LARGO, lasting effect in adjunct therapy with rasagiline given once daily, study): a randomised, double-blind, parallel-group trial. Lancet 365(9463):947–954PubMedCrossRef

32.

Weintraub D, Hauser RA, Elm JJ, Pagan F, Davis MD, Choudhry A (2016) Rasagiline for mild cognitive impairment in Parkinson’s disease: a placebo-controlled trial. Mov Disord 31(5):709–714PubMedCrossRef

33.

Zhang L, Zhang Z, Chen Y, Qin X, Zhou H, Zhang C, Sun H, Tang R, Zheng J, Yi L, Deng L, Li J (2013) Efficacy and safety of rasagiline as an adjunct to levodopa treatment in Chinese patients with Parkinson’s disease: a randomized, double-blind, parallel-controlled, multi-centre trial. Int J Neuropsychopharmacol 16(7):1529–1537PubMedCrossRef

34.

Zhang Z, Shao M, Chen S, Liu C, Peng R, Li Y, Wang J, Zhu S, Qu Q, Zhang X, Chen H, Sun X, Wang Y, Sun S, Zhang B, Li J, Pan X, Zhao G (2018) Adjunct rasagiline to treat Parkinson’s disease with motor fluctuations: a randomized, double-blind study in China. Transl Neurodegener 7:14PubMedPubMedCentralCrossRef

35.

Kaludercic N, Carpi A, Nagayama T, Sivakumaran V, Zhu G, Lai EW, Bedja D, De Mario A, Chen K, Gabrielson KL, Lindsey ML, Pacak K, Takimoto E, Shih JC, Kass DA, Di Lisa F, Paolocci N (2014) Monoamine oxidase B prompts mitochondrial and cardiac dysfunction in pressure overloaded hearts. Antioxid Redox Signal 20(2):267–280PubMedPubMedCentralCrossRef

36.

Dezsi L, Vecsei L (2017) Monoamine oxidase B inhibitors in Parkinson’s disease. CNS Neurol Disord Drug Targets 16(4):425–439PubMedCrossRef

37.

Mazumder MK, Paul R, Phukan BC, Dutta A, Chakrabarty J, Bhattacharya P, Borah A (2018) Garcinol, an effective monoamine oxidase-B inhibitor for the treatment of Parkinson’s disease. Med Hypotheses 117:54–58PubMedCrossRef

38.

Kong P, Zhang B, Lei P, Kong X, Zhang S, Li D, Zhang Y (2015) Neuroprotection of MAO-B inhibitor and dopamine agonist in Parkinson disease. Int J Clin Exp Med 8(1):431–439PubMedPubMedCentral

39.

Hauser RA, Silver D, Choudhry A, Eyal E, Isaacson S (2014) Randomized, controlled trial of rasagiline as an add-on to dopamine agonists in Parkinson’s disease. Mov Disord 29(8):1028–1034PubMedCrossRef

40.

Cereda E, Cilia R, Canesi M, Tesei S, Mariani CB, Zecchinelli AL, Pezzoli G (2017) Efficacy of rasagiline and selegiline in Parkinson’s disease: a head-to-head 3-year retrospective case-control study. J Neurol 264(6):1254–1263PubMedPubMedCentralCrossRef

41.

Chang Y, Wang LB, Li D, Lei K, Liu SY (2017) Efficacy of rasagiline for the treatment of Parkinson’s disease: an updated meta-analysis. Ann Med 49(5):421–434PubMedCrossRef

42.

Elmer LW (2013) Rasagiline adjunct therapy in patients with Parkinson’s disease: post hoc analyses of the PRESTO and LARGO trials. Parkinsonism Relat Disord 19(11):930–936PubMedCrossRef

43.

Stern MB, Marek KL, Friedman J, Hauser RA, LeWitt PA, Tarsy D, Olanow CW (2004) Double-blind, randomized, controlled trial of rasagiline as monotherapy in early Parkinson’s disease patients. Mov Disord 19(8):916–923PubMedCrossRef

44.

Rinaldi D, Assogna F, Sforza M, Tagliente S, Pontieri FE (2018) Rasagiline for dysexecutive symptoms during wearing-off in Parkinson’s disease: a pilot study. Neurol Sci 39(1):141–143PubMedCrossRef

45.

Stocchi F, Rabey JM (2011) Effect of rasagiline as adjunct therapy to levodopa on severity of OFF in Parkinson’s disease. Eur J Neurol 18(12):1373–1378PubMedCrossRef

46.

Elmer L, Schwid S, Eberly S, Goetz C, Fahn S, Kieburtz K, Oakes D, Blindauer K, Salzman P, Oren S, Prisco UL, Stern M, Shoulson I (2006) Rasagiline-associated motor improvement in PD occurs without worsening of cognitive and behavioral symptoms. J Neurol Sci 248(1–2):78–83PubMedCrossRef

47.

Elbers RG, Verhoef J, van Wegen EE, Berendse HW, Kwakkel G (2015) Interventions for fatigue in Parkinson’s disease. Cochrane Database Syst Rev 10:CD010925

48.

Perez-Lloret S, Rascol O (2011) Safety of rasagiline for the treatment of Parkinson’s disease. Expert Opin Drug Saf 10(4):633–643PubMedCrossRef

Title: Rasagiline combined with levodopa therapy versus levodopa monotherapy for patients with Parkinson’s disease: a systematic review
Authors: De-Qi Jiang
Hua-Kun Wang
Yan Wang
Ming-Xing Li
Li-Lin Jiang
Yong Wang
Publication date: 01-01-2020
Publisher: Springer International Publishing
Keywords: Parkinson's Disease
Levodopa
Rasagiline
Published in: Neurological Sciences / Issue 1/2020
Print ISSN: 1590-1874
Electronic ISSN: 1590-3478
DOI: https://doi.org/10.1007/s10072-019-04050-8

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Rasagiline combined with levodopa therapy versus levodopa monotherapy for patients with Parkinson’s disease: a systematic review

Abstract

Objective

Methods

Results

Conclusions

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Objective

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 1/2020

Atypical neuroimaging findings in patients with acquired hepatocerebral degeneration

Ischaemic stroke as first presentation of occult colon neoplasia in a 30-year-old young man with an associated Streptococcus gallolyticus infection causing endocarditis and infectious intracranial aneurysm

Tracking cognitive impairment in multiple sclerosis using the Brain on Track test: a validation study

Neural correlates of different behavioral response to transcranial direct current stimulation between patients in the unresponsive wakefulness syndrome and minimally conscious state

Association of plasma trimethylamine-N-oxide levels with post-stroke cognitive impairment: a 1-year longitudinal study

Lack of evidence for Toxocara infection in Italian myelitis patients